Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SREBF2 | Q12772 | 13/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | ATM | Q13315 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | CDC7 | O00311 | 3/20 | 0.49 |
| ▸ | DBF4 | Q9UBU7 | 3/20 | 0.49 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SREBF1 | P36956 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4286677 | 0.92 | SREBF2 (0.54) | SREBF2MAPTATML3MBTL1KDM4E | |
| SCHEMBL4283901 | 0.88 | SREBF2 (0.58) | SREBF2MAPTATML3MBTL1KDM4E | |
| SCHEMBL4279577 | 0.87 | SREBF2 (0.53) | SREBF2MAPTATML3MBTL1KDM4E | |
| SCHEMBL4293667 | 0.87 | SREBF2 (0.69) | SREBF2MAPTATML3MBTL1KDM4E | |
| SCHEMBL19733079 | 0.82 | SREBF2 (0.56) | SREBF2MAPTATML3MBTL1KDM4E | |
| SCHEMBL4279440 | 0.80 | SREBF2 (0.57) | SREBF2MAPTATML3MBTL1KDM4E | |
| SCHEMBL4286484 | 0.79 | CDC7 (0.60) | SREBF2MAPTATML3MBTL1KDM4E | |
| SCHEMBL19733086 | 0.73 | SREBF2 (0.55) | SREBF2MAPTATML3MBTL1KDM4E | |
| SCHEMBL4286504 | 0.72 | SREBF2 (1.00) | SREBF2MAPTATML3MBTL1KDM4E | |
| SCHEMBL15953491 | 0.72 | SREBF2 (0.64) | SREBF2MAPTATML3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2120580-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE MEDICINE (US) | 2017-12-27 | — | — | EP | claimed |
| US-8778976-B2 | Compositions and methods for the treatment of metabolic disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2014-07-15 | — | — | US | claimed |
| US-20130012538-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2013-01-10 | — | — | US | claimed |
| US-20130005768-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2013-01-03 | — | — | US | claimed |
| US-8207196-B2 | Compositions and methods for the treatment of metabolic disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2012-06-26 | — | — | US | claimed |
| EP-2120580-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | Baylor College Of Medicine (US) | 2009-11-25 | — | — | EP | claimed |
| US-20090131475-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2009-05-21 | — | — | US | claimed |
| WO-2008097835-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2008-08-14 | — | — | WO | claimed |
| US-20180291013-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND RELATED DISORDERS | BAYLOR COLLEGE OF MEDICINE | 2018-10-11 | — | — | US | disclosed |
| US-20180071289-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER AND RELATED HYPERPROLIFERATIVE DISORDERS | UESUGI MOTONARI (JP) | 2018-03-15 | — | — | US | disclosed |
| EP-2120580-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE MEDICINE (US) | 2017-12-27 | — | — | EP | disclosed |
| US-9713613-B2 | Methods and compositions for the treatment of cancer and related hyperproliferative disorders | BAYLOR COLLEGE OF MEDICINE | 2017-07-25 | — | — | US | disclosed |
| US-20160257675-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE MEDICINE (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160221999-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE MEDICINE (US) | 2016-08-04 | — | — | US | disclosed |
| US-20130012538-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2013-01-10 | — | — | US | disclosed |
| US-20130005768-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2013-01-03 | — | — | US | disclosed |
| US-8207196-B2 | Compositions and methods for the treatment of metabolic disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2012-06-26 | — | — | US | disclosed |
| EP-2120580-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | Baylor College Of Medicine (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20090131475-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2009-05-21 | — | — | US | disclosed |
| WO-2008097835-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071289-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER AND RELATED HYPERPROLIFERATIVE DISORDERS | HCCS, PCNA, MKI67 | SREBF2 1767/4885MAPT 4275/4885ATM 892/4885 |
| US-20180291013-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND RELATED DISORDERS | FABP4, LIPC, PNLIP | SREBF2 17/4885MAPT 3356/4885ATM 1467/4885 |
| US-20130012538-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | FABP4, LIPC, FABP1 | SREBF2 31/4885MAPT 3510/4885ATM 1753/4885 |
| US-20130005768-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | FABP4, LIPC, FABP1 | SREBF2 31/4885MAPT 3510/4885ATM 1753/4885 |
| US-20160257675-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | FABP4, LIPC, FABP1 | SREBF2 31/4885MAPT 3510/4885ATM 1753/4885 |
| US-20160221999-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | FABP4, LIPC, FABP1 | SREBF2 31/4885MAPT 3510/4885ATM 1753/4885 |
| US-20090131475-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | FABP4, LIPC, FABP1 | SREBF2 32/4885MAPT 3438/4885ATM 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.